Latest Articles
Professor Avery’s AI research reveals 20% have undiagnosed endometriosis - The Weekly Times
Professor Avery’s AI research reveals 20% have undiagnosed endometriosis The Weekly Times
Published: May 18, 2026, 9:17 p.m.
Yana Aznavour, MD, PhD, on a non-invasive menstrual blood diagnostic platform for endometriosis - Contemporary OB/GYN
Yana Aznavour, MD, PhD, on a non-invasive menstrual blood diagnostic platform for endometriosis Contemporary OB/GYN
Published: May 18, 2026, 8:17 p.m.
Sac-TMT Significantly Improves PFS/OS in Pretreated Endometrial Cancer - CancerNetwork
Sac-TMT Significantly Improves PFS/OS in Pretreated Endometrial Cancer CancerNetwork
Published: May 18, 2026, 7:33 p.m.
Professor Avery’s AI research reveals 20% have undiagnosed endometriosis - Adelaide Now
Professor Avery’s AI research reveals 20% have undiagnosed endometriosis Adelaide Now
Published: May 18, 2026, 5:52 p.m.
‘I am truly grateful’: Endometriosis care, fertility treatment make motherhood possible - UChicago Medicine
‘I am truly grateful’: Endometriosis care, fertility treatment make motherhood possible UChicago Medicine
Published: May 18, 2026, 4:39 p.m.
Sinn Féin to hold Endometriosis event - sinnfein.ie
Sinn Féin to hold Endometriosis event sinnfein.ie
Published: May 18, 2026, 4:01 p.m.
Professor Avery’s AI research reveals 20% have undiagnosed endometriosis - Herald Sun
Professor Avery’s AI research reveals 20% have undiagnosed endometriosis Herald Sun
Published: May 18, 2026, 3:08 p.m.
Easing pain: Way to slash endometriosis diagnosis by years - NT News
Easing pain: Way to slash endometriosis diagnosis by years NT News
Published: May 18, 2026, 2:19 p.m.
Merck reports positive Phase 3 results for uterine cancer drug - Voice of Healthcare
Merck reports positive Phase 3 results for uterine cancer drug Voice of Healthcare
Published: May 18, 2026, 11:29 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire
Published: May 18, 2026, 10:45 a.m.
Link copied to clipboard!